DURECT Corporation

DRRX

US2666055007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-16 EDT			5-day change	1st Jan Change
1.36 ^USD	+0.74%		+10.57%	+130.51%

05-21	DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	CI
05-21	Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	MT

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

January 04, 2021 at 08:30 am

DURECT Corporation announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020.

Latest news about DURECT Corporation

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	05-21	CI
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	05-21	MT
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment	05-21	MT
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	05-14	MT
Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024	05-13
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Earnings Flash (DRRX) DURECT CORPORATION Reports Q1 Revenue $1.8M, vs. Street Est of $2.7M	05-13	MT
Transcript : DURECT Corporation, Q4 2023 Earnings Call, Mar 27, 2024	03-27
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M	03-27	MT
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
North American Morning Briefing : Stocks Edge -2-	03-27	DJ
North American Morning Briefing : Stock Futures -2-	03-19	DJ
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada	03-04	CI
DURECT Corporation(NasdaqCM:DRRX) dropped from S&P Global BMI Index	12-18	CI
Transcript : DURECT Corporation, Q3 2023 Earnings Call, Nov 13, 2023	11-13
Earnings Flash (DRRX) DURECT CORPORATION Reports Q3 Revenue $1.7M, vs. Street Est of $2.5M	11-13	MT
DURECT Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
North American Morning Briefing : Investors Weigh -2-	11-10	DJ
JonesTrading Downgrades Durect to Hold From Buy	11-09	MT
North American Morning Briefing : Traders Await -2-	11-09	DJ
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	11-08	MT
Sector Update: Health Care	11-08	MT
Top Midday Decliners	11-08	MT
HC Wainwright Downgrades Durect to Neutral From Buy	11-08	MT

DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for DURECT Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.36 USD

Average target price

6.75 USD

Spread / Average Target

+396.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DURECT CORPORATION	+130.51%	42.21M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.06%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.96%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs